COPENHAGEN (Reuters) -Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, the firm said ...
Shares of Regeneron Pharmaceuticals (REGN) fell about 12% on Monday, making the biotech company the worst-performing stock in ...
Regeneron's shares fell 12% in morning trade on Monday after the company's experimental treatment missed the main goal in ...
Regeneron has reported that its fianlimab antibody targeting LAG-3, an immune checkpoint proposed as a cancer target, has ...
Despite UK and EU rules aimed at boosting clinical trials reporting and transparency, a new report by the UK House of Commons’ Science and Technology Committee finds that nearly half of clinical ...
A new study finds just 6% of clinical trials used to approve new drugs in the U.S. reflect the country's racial and ethnic makeup, with an increasing trend of trials underrepresenting Black and ...
A retrospective analysis found that strategic decisions and recruitment challenges were leading contributors to head and neck squamous cell carcinoma trial failures, accounting for 29.5% and 26.0% of ...
Thirty-two percent of confirmatory trials demonstrated an overall survival benefit when the drug was converted from accelerated approval to regular approval. Confirmatory trials for cancer drugs that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results